The past and fu­ture of an­ti­bod­ies, as told through HIV; An­oth­er big phar­ma joins CD47 game; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Ja­son Mast’s deeply re­port­ed spe­cial on an­ti­body de­vel­op­ment should keep you quite busy, but if you want to dive deep­er in­to the top­ic over the week­end, be sure to check out the we­bi­nar dis­cus­sion with top ex­perts in the field, mod­er­at­ed by Kyle Blanken­ship.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.